AIMT long call

Still got the other biotech plays on deck, but read up on $AIMT a couple of days ago.  I went long a Feb 21 $35.00 Call at $3.10 on Tuesday.  They are awaiting word from FDA on approval for the only “drug” for Peanut Allergy.  Their main competitor failed Phase 3, and they had an Advisory Committee meeting recently which voted 7-2 in favor of it.  It’s a specific dose, de-fatted peanut protein which is given in increasing titrating amounts until the patients can have no adverse effects from eating about a single peanut.  Figured I’d throw my hat in the ring– FDA is expected to give thumbs up or down late January, so maybe hold it for a week or so.